Literature DB >> 2479745

A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine.

T Miyasaka1, H Tanaka, M Baba, H Hayakawa, R T Walker, J Balzarini, E De Clercq.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2479745     DOI： 10.1021/jm00132a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  34 in total

1.  Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.

Authors:  Mihai V Putz; Nicoleta A Dudaș; Adriana Isvoran
Journal:  Int J Mol Sci       Date:  2015-08-18       Impact factor: 5.923

2.  Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.

Authors:  J Balzarini; A Karlsson; M J Pérez-Pérez; M J Camarasa; W G Tarpley; E De Clercq
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

Review 3.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

4.  Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives.

Authors:  M Baba; E De Clercq; S Iida; H Tanaka; I Nitta; M Ubasawa; H Takashima; K Sekiya; K Umezu; H Nakashima
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

5.  Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus.

Authors:  J Balzarini; W G Brouwer; D C Dao; E M Osika; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

6.  SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2.

Authors:  R W Buckheit; K Watson; V Fliakas-Boltz; J Russell; T L Loftus; M C Osterling; J A Turpin; L A Pallansch; E L White; J W Lee; S H Lee; J W Oh; H S Kwon; S G Chung; E H Cho
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

7.  Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.

Authors:  J Balzarini; A Karlsson; A M Vandamme; M J Pérez-Pérez; H Zhang; L Vrang; B Oberg; K Bäckbro; T Unge; A San-Félix
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-01       Impact factor: 11.205

8.  Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  P L Boyer; M J Currens; J B McMahon; M R Boyd; S H Hughes
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains.

Authors:  J Balzarini; M Baba; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

10.  Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro.

Authors:  M Baba; M Ito; S Shigeta; H Tanaka; T Miyasaka; M Ubasawa; K Umezu; R T Walker; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.